Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821707 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17687796 | 0.83 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17687793 | 0.83 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23608592 | 0.83 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL28850071 | 0.83 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1823872 | 0.83 | PIK3CD (0.42) | PIK3CDPIK3CA | |
| SCHEMBL1823877 | 0.83 | PIK3CD (0.42) | PIK3CDPIK3CA | |
| SCHEMBL5671217 | 0.82 | PIK3CD (0.48) | PIK3CDPIK3CA | |
| SCHEMBL23580127 | 0.81 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23608593 | 0.81 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951716-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1951716-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070179125-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007059299-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179125-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, MAP3K5, MAP3K20 | PIK3CD 53/4885PIK3CA 18/4885PIK3CB 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.